STAT+: As drug price target deadline looms, pharma companies weigh options
Trump's most-favored nation plan would tie U.S. drug prices to those in other countries
WASHINGTON — Trump administration officials are expected to release more details on their plan to lower prescription drug prices in the coming days and have been meeting with pharmaceutical industry leaders about the potential impacts.
The drug companies, in turn, have been gaming out possible scenarios — and strategizing how they may respond to the White House, five people involved in the planning said.
Administration officials announced on May 12 a new policy that sought to lower U.S. drug prices to put them in line with what other countries pay, a so-called most-favored nation plan. President Trump signed an executive order that day requiring health secretary Robert F. Kennedy Jr. to set price goals within 30 days, setting the stage for negotiations between the drug companies and the administration.
